MEIP लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 23:00):

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer...

Stats
आज की मात्रा	8 618.00
औसत मात्रा	20 800.00
बाजार मूल्य	20.65M
EPS	$0 ( 2024-02-08 )
अगली कमाई की तारीख	( $-1.520 ) 2024-05-09
Last Dividend	$1.750 ( 2023-11-16 )
Next Dividend	$0 ( N/A )
P/E	1.040
ATR14	$0.0220 (0.71%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-18	Flynn James P	Buy	10 000	Stock Option (Right to Buy)
2023-12-18	Flynn James P	Buy	6 700	Stock Option (Right to Buy)
2023-12-18	Wood Steven D	Buy	10 000	Stock Option (Right to Buy)
2023-12-18	Wood Steven D	Buy	6 700	Stock Option (Right to Buy)
2023-12-18	Wood Steven D	Buy	10 000	Stock Option (Right to Buy)

INSIDER POWER
92.96
Last 96 transactions
Buy: 9 932 993 \| Sell: 849 643

MEI Pharma Inc सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध
RIDE	0.969
IMBI	0.968
ASLE	0.962
EVOK	0.961
EBIX	0.961
VRAY	0.96
TBLT	0.958
MSEX	0.955
AGRI	0.947
CFRX	0.947

10 सबसे अधिक नकारात्मक सहसंबंध
VMGA	-0.965
ADAL	-0.965
HCNE	-0.959
BRIV	-0.959
TIOAU	-0.958
VLAT	-0.958
RNLC	-0.956
KVSC	-0.955
EGLE	-0.955
LDHA	-0.954

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

MEI Pharma Inc वित्तीय

Annual	2023
राजस्व:	$48.82M
सकल लाभ:	$47.00M (96.28 %)
EPS:	$-4.78

FY	2023
राजस्व:	$48.82M
सकल लाभ:	$47.00M (96.28 %)
EPS:	$-4.78

FY	2022
राजस्व:	$40.70M
सकल लाभ:	$39.46M (96.97 %)
EPS:	$-8.80

FY	2021
राजस्व:	$25.54M
सकल लाभ:	$24.13M (94.49 %)
EPS:	$-0.450

Financial Reports:

No articles found.

MEI Pharma Inc Dividends

(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$1.750 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

MEI Pharma Inc Dividend Information - Dividend Knight

Dividend Sustainability Score: 5.51 - average (50.95%) | Divividend Growth Potential Score: 0 - No dividend expected

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$1.750	2023-11-16
Last Dividend	$1.750	2023-11-16
Next Dividend	$0	N/A
Payout Date	2023-12-06
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$1.750	--
Avg. Dividend % Per Year	11.67%	--
Score	4.75	--
Div. Sustainability Score	5.51
Div.Growth Potential Score	0
Div. Directional Score	2.48	--

Next Divdend (Est)
(2024-05-03)

$3.50 Estimate 2.50 %

Dividend Stability

0.20 Very Poor

Dividend Score

4.75

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
2023	$1.750	35.00%
2024	$0	0.00%

Dividend Commentary

With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.286	1.500	4.27	6.41	[0 - 0.5]
returnOnAssetsTTM	0.265	1.200	1.173	1.408	[0 - 0.3]
returnOnEquityTTM	0.416	1.500	6.49	9.73	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	8.23	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	7.40	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	0.644	1.500	7.54	10.00	[0.2 - 2]
debtRatioTTM	0.153	-1.500	7.45	-10.00	[0 - 0.6]
interestCoverageTTM	-16.44	1.000	-7.20	-7.20	[3 - 30]
operatingCashFlowPerShareTTM	-7.95	2.00	-2.65	-5.30	[0 - 30]
freeCashFlowPerShareTTM	-7.95	2.00	-3.97	-7.95	[0 - 20]
debtEquityRatioTTM	0.202	-1.500	9.19	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.980	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.219	1.000	7.63	7.63	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-4.40	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0.925	0.800	7.17	5.73	[0.5 - 2]
Total Score				5.51

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	0.980	1.000	-0.00198	0	[1 - 100]
returnOnEquityTTM	0.416	2.50	7.74	9.73	[0.1 - 1.5]
freeCashFlowPerShareTTM	-7.95	2.00	-2.65	-7.95	[0 - 30]
dividendYielPercentageTTM	57.19	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-7.95	2.00	-2.65	-5.30	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-0.729	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-0.560

MEI Pharma Inc

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.